Stock 2269 WUXI BIOLOGICS (CAYMAN) INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

WuXi Biologics (Cayman) Inc. Stock Hong Kong S.E.

Equities

2269

KYG970081090

Biotechnology & Medical Research

Financials

Sales 2024 * 18.12B 2.49B 19.47B 3.41B Sales 2025 * 20.99B 2.89B 22.55B 3.95B Capitalization 44.59B 6.14B 47.91B 8.39B
Net income 2024 * 3.85B 529M 4.13B 724M Net income 2025 * 4.61B 634M 4.95B 867M EV / Sales 2024 * 2.06 x
Net cash position 2024 * 7.25B 998M 7.79B 1.36B Net cash position 2025 * 8.19B 1.13B 8.8B 1.54B EV / Sales 2025 * 1.73 x
P/E ratio 2024 *
12 x
P/E ratio 2025 *
9.99 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85%
More Fundamentals * Assessed data

Chart WuXi Biologics (Cayman) Inc.

Dynamic Chart

Latest news about WuXi Biologics (Cayman) Inc.

Bank of China Downgrades Wuxi Biologics (Cayman) to Hold From Buy, Price Target is HK$14 MT
Wuxi Biologics Terms US Plant's Expansion Halt as Normal Business Adjustment MT
WuXi Biologics Surges to 19-Month High Wednesday on Hopes of Avoiding US Ban MT
US lawmakers ask FBI for briefing on GenScript Biotech's links to China RE
US lawmakers ask FBI for briefing on GenScript Biotech's links to China RE
China stocks rise as industrial profits grow; energy, semiconductor shares lead gains RE
Wuxi Biologics (Cayman) Maintains it is Not a Security Threat After House Bill Changes; Stocks Drop 3% MT
US House committee advances bill to restrict BGI, WuXi AppTec RE
US House committee to vote on bill to restrict BGI, WuXi AppTec RE
US Congress Drafts Bill Asking Drug Firms to Unlink from Chinese Biotech Firms MT
WuXi Shares Volatile as U.S. Bill Revised to Set Deadline for Decoupling DJ
U.S. bill to restrict WuXi AppTec, other Chinese biotech cos revised to give more time to cut ties RE
Pacific Assets Trust cautiously optimistic after outpacing benchmark AN
Wuxi Biologics Inc. Announces Retirement of Weichang Zhou as Chief Technology Officer and President of Global Biologics Development and Operations and Re-Designates as Non-Executive Director and Honorary President of Global Biologics Development and Operations and Senior Advisor to Chief Executive Officer CI
WuXi Biologics' 2023 Profit Falls 23% Despite Revenue Jump MT
More news

Latest transcript on WuXi Biologics (Cayman) Inc.

Logo WuXi Biologics (Cayman) Inc.
WuXi Biologics Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:00 AM
More transcripts

Analyst Recommendations on WuXi Biologics (Cayman) Inc.

Bank of China Downgrades Wuxi Biologics (Cayman) to Hold From Buy, Price Target is HK$14 MT
Wuxi Biologics (Cayman) Maintains it is Not a Security Threat After House Bill Changes; Stocks Drop 3% MT
Nomura Adjusts Wuxi Biologics' Price Target to HK$53.65 From HK$58.44, Keeps at Buy MT
Nomura Adjusts Wuxi Biologics’ Price Target to HK$58.44 From HK$82.69, Keeps at Buy MT
Nomura Adjusts Wuxi Biologics' Price Target to HK$82.69 From HK$86.68, Keeps at Buy MT
More recommendations

Press releases WuXi Biologics (Cayman) Inc.

WuXi Biologics Named to MSCI ESG Leaders Indexes for Second Consecutive Year AQ
WuXi Biologics Cayman : Named to MSCI ESG Leaders Indexes for Second Consecutive Year PU
WuXi Biologics Enhances Manufacturing Capability with the Installation of Three 5,000L Single-Use Bioreactors AQ
WuXi facility boosts bioprocessing capacity with new bioreactors AQ
WuXi Biologics Cayman : Releases 2023 ESG Report Demonstrating Strong Sustainability Commitment PU
More press releases

News in other languages on WuXi Biologics (Cayman) Inc.

MÄRKTE ASIEN/Yen auf 34-Jahres-Tief stützt Kurse in Tokio
MÄRKTE ASIEN/Uneinheitlich - Schwacher Yen stützt Kurse in Tokio
MÄRKTE ASIEN/Leichter - Gewinnmitnahmen drücken Nikkei-Index um 1,2%
MÄRKTE ASIEN/Tokio und Seoul leichter - Schanghai und Hongkong freundlich
MÄRKTE ASIEN/Freundlich - Sydney, Seoul und Hongkong fest
More news

Managers and Directors - WuXi Biologics (Cayman) Inc.

Managers TitleAgeSince
Zhi Sheng Chen CEO
 Chief Executive Officer 52 11-05-31
Ming Tu DFI
 Director of Finance/CFO 54 21-08-22
Ji Jie Gu CTO
 Chief Tech/Sci/R&D Officer 57 -
Members of the board TitleAgeSince
Jackson Tai BRD
 Director/Board Member 73 23-05-05
William Keller BRD
 Director/Board Member 75 17-05-16
Ge Li CHM
 Chairman 56 10-04-30
More insiders

Company Profile

WuXi Biologics (Cayman) Inc is an investment holding company principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry. The Company mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The Company mainly conducts its business in the domestic and overseas markets.
Sector
Biotechnology & Medical Research
Calendar
2024-08-18 - Q2 2024 Earnings Release (Projected)
Related indices
HONG KONG HANG SENG
More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.20% 121B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+19.67% 113B
ARGENX SE Stock argenx SE
+18.95% 26.02B
BIONTECH SE Stock BioNTech SE
-23.86% 19.39B
GENMAB A/S Stock Genmab A/S
-19.03% 15.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.90% 15.09B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.14% 15.06B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+63.85% 14.93B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.49% 13.85B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 2269 Stock
  4. 2269 Stock